JP2022517109A5 - - Google Patents
Info
- Publication number
- JP2022517109A5 JP2022517109A5 JP2021540533A JP2021540533A JP2022517109A5 JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5 JP 2021540533 A JP2021540533 A JP 2021540533A JP 2021540533 A JP2021540533 A JP 2021540533A JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- cancers
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791979P | 2019-01-14 | 2019-01-14 | |
| US62/791,979 | 2019-01-14 | ||
| PCT/US2020/013264 WO2020150115A1 (en) | 2019-01-14 | 2020-01-13 | Nlrp3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517109A JP2022517109A (ja) | 2022-03-04 |
| JP2022517109A5 true JP2022517109A5 (cg-RX-API-DMAC7.html) | 2022-09-05 |
| JP7335341B2 JP7335341B2 (ja) | 2023-08-29 |
Family
ID=69469246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540533A Active JP7335341B2 (ja) | 2019-01-14 | 2020-01-13 | Nlrp3モジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12391675B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3911641A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7335341B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102865929B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113286786A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020150115A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3911642B1 (en) | 2019-01-14 | 2026-06-10 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| KR20240055035A (ko) * | 2021-08-31 | 2024-04-26 | 니뽄 다바코 산교 가부시키가이샤 | 6-아미노피라졸로피리미딘 화합물 및 그 의약 용도 |
| CN115282280A (zh) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | TGF-β1信号抑制剂的新用途 |
| EP4671246A1 (en) * | 2023-02-24 | 2025-12-31 | Japan Tobacco Inc. | COMPOSITE OF 6-ALCOXYPYRAZOLOPYRIMIDINE AND ITS PHARMACEUTICAL USE |
| TW202448887A (zh) * | 2023-02-24 | 2024-12-16 | 日商日本煙草產業股份有限公司 | 取代吡唑并嘧啶化合物及其醫藥用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| JP2014518267A (ja) | 2011-06-27 | 2014-07-28 | 杏林製薬株式会社 | 細菌感染症の治療のための架橋二環式化合物 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| EP3445761A1 (en) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| TWI674261B (zh) * | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| ES3002968T3 (en) * | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| EP3911642B1 (en) * | 2019-01-14 | 2026-06-10 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| KR102815870B1 (ko) * | 2019-01-14 | 2025-05-30 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제 |
-
2020
- 2020-01-13 CN CN202080008819.6A patent/CN113286786A/zh active Pending
- 2020-01-13 EP EP20703911.6A patent/EP3911641A1/en active Pending
- 2020-01-13 WO PCT/US2020/013264 patent/WO2020150115A1/en not_active Ceased
- 2020-01-13 JP JP2021540533A patent/JP7335341B2/ja active Active
- 2020-01-13 US US17/422,512 patent/US12391675B2/en active Active
- 2020-01-13 KR KR1020217025495A patent/KR102865929B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534168A5 (cg-RX-API-DMAC7.html) | ||
| JP2021522249A5 (cg-RX-API-DMAC7.html) | ||
| JP2021534158A5 (cg-RX-API-DMAC7.html) | ||
| JP7274450B2 (ja) | 癌を処置するための医薬組合せ | |
| ES2290199T3 (es) | Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce. | |
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2025024006A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510191A5 (cg-RX-API-DMAC7.html) | ||
| KR20210075992A (ko) | Sting 작동 화합물 | |
| WO2019136298A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| JP2022517110A5 (cg-RX-API-DMAC7.html) | ||
| ES2653990T3 (es) | Benzodiazepinas para tratamiento del cáncer de pulmón de células pequeñas | |
| JP2016523974A5 (cg-RX-API-DMAC7.html) | ||
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| RU2020113749A (ru) | Аналоги таиланстатина | |
| JP2023506787A5 (cg-RX-API-DMAC7.html) | ||
| MX2013008749A (es) | Agente terapeutico o profilactico para caquexia. | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2002544231A (ja) | ガンを治療するための組成物とet743の使用 | |
| EP4447973A1 (en) | Use of combination therapy for treating cancer | |
| EP3996749A1 (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| RU2013143520A (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
| JP2024542633A5 (cg-RX-API-DMAC7.html) | ||
| RU2334517C2 (ru) | Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство | |
| PT1885187E (pt) | Métodos para o tratamento de cancro resistente a fármacos |